ロード中...
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
BACKGROUND: Targeted therapies significantly improve clinical outcomes among patients with metastatic renal cell carcinoma (mRCC). Several new agents have been approved for first- and second-line use. However, there is a lack of compelling evidence comparing sequencing strategies, and available comp...
保存先:
| 出版年: | Pathol Oncol Res |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Netherlands
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7471136/ https://ncbi.nlm.nih.gov/pubmed/32291570 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12253-020-00809-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|